Guselkumab Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the QUASAR Phase 3 Induction Study

被引：0

作者：

Bressler, Brian ^{[1
]}

Feagan, Brian G. ^{[2
]}

Panes, Julian ^{[3
]}

Lichtenstein, Gary R. ^{[4
]}

Huang, Kuan-Hsiang G. ^{[5
]}

Germinaro, Matthew ^{[5
]}

Pandya, Dwiti ^{[5
]}

Han, Chenglong ^{[6
]}

Miao, Ye ^{[5
]}

Zhang, Hongyan ^{[5
]}

Lateef, Syed ^{[7
]}

Petroniene, Rima ^{[8
]}

Rayyan, Yaser ^{[9
]}

Peyrin-Biroulet, Laurent ^{[10
,11
]}

Rubin, David T. ^{[12
]}

Hisamatsu, Tadakazu ^{[13
]}

机构：

[1] St Pauls Hosp, Vancouver, BC, Canada

[2] Western Univ, London, ON, Canada

[3] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Catalonia, Spain

[4] Univ Penn, Philadelphia, PA USA

[5] Janssen Res & Dev LLC, Spring House, PA USA

[6] Janssen Global Serv LLC, Malvern, PA USA

[7] Gastro Hlth, Kissimmee, FL USA

[8] Barrie GI Associates, Barrie, ON, Canada

[9] Univ Jordan, Amman, Jordan

[10] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France

[11] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France

[12] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA

[13] Kyorin Univ, Sch Med, Tokyo, Tokyo, Japan

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S1060

引用

页码：S807 / S808

页数：2

共 50 条

[21] The Efficacy of Induction Treatment With Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 QUASAR Induction Study Results at Week 12 by Prior Advanced Therapy History
Bressler, Brian
Peyrin-Biroulet, Laurent
Allegretti, Jessica R.
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Shipitofsky, Nicole
Miao, Ye
Zhang, Hongyan
Bortlik, Martin
Hlavaty, Tibor
Fujii, Toshimitsu
Feagan, Brian G.
Sands, Bruce E.
Dignass, Axel
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S806 - S807
[22] Improvement in Inflammatory Biomarker Levels Through Week 12 in Moderately to Severely Active Ulcerative Colitis Patients Treated With Guselkumab: Results From the Phase 3 QUASAR Induction Study
Hisamatsu, Tadakazu
Peyrin-Biroulet, Laurent
Dignass, Axel
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Houck, Nicole
Miao, Ye
Zhang, Hongyan
Argollo, Marjorie
Takeuchi, Ken
Filip, Rafal
Allegretti, Jessica R.
Feagan, Brian G.
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S810 - S810
[23] Impact of Guselkumab Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 12 Results From the Phase 3 QUASAR Induction Study
Panes, Julian
Sands, Bruce E.
Peyrin-Biroulet, Laurent
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Sridhar, Sunandini
Branigan, Patrick
Miao, Ye
Zhang, Hongyan
Hebuterne, Xavier
Gyokeres, Tibor
Hirai, Fumihito
Hisamatsu, Tadakazu
Rubin, David T.
Feagan, Brian G.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S874 - S875
[24] The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
Dignass, A.
Rubin, D.
Bressler, B.
Huang, K. H.
Shipitofsky, N.
Germinaro, M.
Zhang, H.
Johanns, J.
Feagan, B.
Sandborn, W.
Sands, B.
Hisamatsu, T.
Lichtenstein, G.
Panes, J.
Allegretti, J.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I025 - I026
[25] Health-Related Quality of Life in Chinese Patients with Mild and Moderately Active Ulcerative Colitis
Zheng, Kai
Zhang, Shengsheng
Wang, Chuijie
Zhao, Wenxia
Shen, Hong
PLOS ONE, 2015, 10 (04):
[26] The Effect of Guselkumab Induction Therapy on Inflammatory Biomarkers in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Results Through Week 12
Lichtenstein, Gary
Dignass, Axel
Sandborn, William J.
Huang, Kuan-Hsiang
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Chen, Baili
Chen, Minhu
Hisamatsu, Tadakazu
Feagan, Brian G.
Panes, Julian
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S587 - S587
[27] Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
Rubin, David T.
Allegretti, Jessica R.
Panes, Julian
Shipitofsky, Nicole
Yarandi, Shadi S.
Huang, Kuan-Hsiang Gary
Germinaro, Matthew
Wilson, Rebbecca
Zhang, Hongyan
Johanns, Jewel
Feagan, Brian G.
Hisamatsu, Tadakazu
Lichtenstein, Gary R.
Bressler, Brian
Peyrin-Biroulet, Laurent
Sands, Bruce E.
QUASAR Study Grp
LANCET, 2025, 405 (10472): : 33 - 49
[28] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Panes, J.
Rubin, D. T.
Vermeire, S.
Lindsay, J. O.
Sands, B. E.
Su, C.
Friedman, G.
Zhang, H.
Kayhan, C.
Manuchehri, A.
Healey, P.
GUT, 2017, 66 : A121 - A122
[29] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Panes, Julian
Rubin, David T.
Vermeire, Severine
Lindsay, James O.
Sands, Bruce E.
Su, Chinyu
Friedman, Gary
Zhang, Haiying
Kayhan, Cem
Manuchehri, Alireza
Healey, Paul J.
GASTROENTEROLOGY, 2017, 152 (05) : S601 - S602
[30] Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis
Panes, J.
Rubin, D. T.
Vermeire, S.
Lindsay, J. O.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S315 - S317

← 1 2 3 4 5 →